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Amin Alousi1Anti-Tumor Necrosis Factor Alpha (TNF-a) therapy with infliximab has shown to be effective for patients
with steroid-refractory acute graft-versus-host disease (aGVHD). An open-labeled, phase III trial was con-
ducted to determine if the addition of infliximab to steroids could improve results for patients with newly
diagnosed grade II-IV aGVHD. A total of 63 patients were randomized either to 2 mg/kg/day methylprednis-
olone (MP) or infliximab1 MP. Average age was 47 years (range: 20-70 years); 64% were male. Fifty-three
percent and 51% of patients received a matched-sibling and/or bone marrow (BM) graft. Sixty-seven percent
had grade II, 33% grade III-IV aGVHD; 62% had skin, 53% gastrointestinal (GI), and 7% had liver involvement.
At days 7 and 28, the response rate for infliximab1MP versus MP was 52% versus 78%, P5.03 and 62% ver-
sus 58%, P5.7, respectively. Cumulative incidences of GVHD-related mortality, nonrelapse mortality (NRM),
and overall survival (OS) were not significantly different between the 2 groups (GVHD-related mortality:
38% versus 32%, P5.6; NRM: 52% versus 36%, P5.3; OS: 17% and 28%, P5.4 for infliximab1 MP versus
MP, respectively). Patients with newly diagnosed aGVHD derive no benefit from the addition of anti-TNF-
a therapy with infliximab when compared to corticosteroids alone.
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Graft-versus-host disease (GVHD) remains amajor
limitation of allogeneic hematopoietic stem cell trans-
plantation (HSCT), with the acute form of it occurring
in approximately 20% to 50% of patients [1-4]. Corti-
costeroids still remain the standard initial therapy [5].
Unfortunately, only 50% of patients with grade II or
greater acute GVHD (aGVHD) will respond to this
initial therapy, with the remaining patients being unre-1Department of Stem Cell Transplantation and Cellular
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6/j.bbmt.2009.08.003sponsive or steroid resistant [6]. The outcome for those
with steroid-refractory aGVHD is poor, with a mortal-
ity rate of about 70%, irrespective of the type of second-
ary therapy [7]. Strategies that included either higher
doses of corticosteroids [8] or their combination with
an additional agent, such as antithymocyte globulin
(ATG) [9] or daclizumab [10], have not proved benefi-
cial. Thus, better prophylaxis and upfront therapies
are of vital importance to prevent progression to steroid
refractory disease.
The pathophysiology of aGVHD has been divided
in 3 phases [11]. The first phase occurs as a result of tis-
sue damage resulting from toxicity associated with the
conditioning chemo- or radiotherapy employed prior
to transplant. Damaged tissues create an inflammatory
milieu consisting of cytokines, including tumor necro-
sis factor-alpha (TNF-a), interleukin-1 (IL-1), and
interferon gamma (IFN-g). In the second phase, recip-
ient and donor antigen-presenting cells (APC) along
with inflammatory cytokines trigger the activation of
donor-derived T cells, which expand and differentiate
into effector cells. In the third phase, the effector
phase, activated donor T cells mediate cytotoxicity
against target host cells through Fas-Fas ligand inter-
actions, perforin-granzyme B, and the further1555
Table 1. Patient Characteristics
MP n528 (%)
Inflix +MP
n529 (%)
P-
Value
Age (median, range) 48 years
(20-70 years)
49 years
(22-65 years)
.9
Sex M/F 21 / 7 17 / 12 .3
Disease status at TP
(remission/chronic
phase)
10 (36) 7 (24) .4
Diagnosis
ALL 3 (11) 2 (7)
AML 9 (32) 14 (48)
CLL 5 (18) 1 (3)
CML 4 (14) 1 (3)
Lymphoma 3 (11) 6 (21)
Hodgkin 2 (7) 0 (0)
Myeloma 2 (7) 2 (7)
Other 0 (0) 3 (10)
Donor type .9
Matched sibling 15 (54) 15 (52)
Matched Unrelated 10 (36) 10 (34)
1 Ag MM rel/unrel 2 / 1 (11) 3 / 1 (13)
Preparative regimen .3
Reduced intensity 8 (29) 3 (10)
Myeloablative 20 (71) 26 (90)
Cell type .9
BM 14 (50) 15 (52)
PBPC 14 (50) 14 (48)
GVHD prophylaxis .6
Tacro/MTX 24 (86) 26 (90)
Other 4 (14) 3 (10)
Median days between
TP and therapy
35 (9-222) 28 (13-207) .09
Grade aGVHD at study
entry
.5
2 19 (68) 19 (65)
3 9 (32) 9 (31)
4 0 1 (03)
Skin stage at study
entry
1556 Biol Blood Marrow Transplant 15:1555-1562, 2009D. R. Couriel et al.production of cytokines, such as TNF-a [12]. Thus
TNF-a, which is mainly produced by monocytes and
macrophages and secondarily by T lymphocytes and
natural killer (NK) cells, has been implicated in the
pathophysiology of GVHD at each of these steps in
the process [13]. In support of the central role for
TNF-a has been the correlation between high serum
levels of TNF-a and increased incidence of GVHD
in transplant recipients [14]. Therefore, therapies di-
rected at reducing the amount of circulating TNF-
a have been hypothesized as one method to treat
aGVHD.
Infliximab, which is currently approved for the
treatment of patients with rheumatoid arthritis and
Crohn’s Disease, is a chimeric mouse/human IgG1
antibody that binds with high affinity to soluble and
transmembrane forms of human TNF-a [15]. Binding
of the antibody to soluble TNF-a results in neutraliz-
ing its activity, whereas binding to the transmembrane
form results in cell lysis through complement medi-
ated processes [16]. Results from retrospective studies
evaluating the use of infliximab in the setting of
steroid-refractory GVHD have shown response rates
ranging from 59% to 67%, better in patients with
intestinal GVHD [17,18].
Therefore, we decided to evaluate infliximab ear-
lier in the treatment of aGVHD. This is a prospective,
randomized phase III study that compares standard
therapy with corticosteroids versus infliximab in addi-
tion to standard therapy for the initial treatment of
grade II-IV aGVHD.0 10 (36) 12 (41)
1-2 5 (18) 4 (14)
3 13 (46) 13 (45)
GI stage at study
entry
0 13 (46) 14 (48)
1-2 12 (43) 12 (42)
3-4 3 (11) 3 (10)
UGI stage at study
entry
0 25 (89) 25 (86)
1 3 (11) 4 (14)
Liver stage at
study entry
0 25 (89) 28 (97)
1 2 (07) 1 (03)
2 1 (04) 0 (0)
1-Ag MM rel indicates 1-antigen mismatch-related donor; aGVHD;
acute graft-versus-host disease; ALL, acute lymphoblastic leukemia;
AML, acute myelogenous leukemia; BM, bone marrow; CML, chronic
myelogenous leukemia; F, female; inflix, infliximab; M, male; MM, mis-
match; MP, methylprednisolone; MTX, methotrexate; PBPC, peripheral
blood progenitor cell; tacro, tacrolimus; TP, transplant; tmt, treatment;
UGI, upper gastrointestinal; unrel, unrelated.PATIENTS
Patients 18 years of age or olderwere eligible for in-
clusion if they developed grade II or greater aGVHD
involving the skin, liver, or gastrointestinal (GI) tract
or any organ combination following an allogeneic
bonemarrow (BM) or peripheral blood stem cell trans-
plantation (PBSCT). The diagnoses are shown on
Table 1, and these were considered to be at low risk of
relapse if they were in complete remission at the time
of transplant or in chronic phase in the case of chronic
myelogenous leukemia (CML). Patients received condi-
tioning regimens that were myeloablative (MA) or re-
duced intensity (RIC). Preparative regimens were
considered myeloablative (MA) if they were expected
to produce profound pancytopenia for more than 28
days without transplantation and if, after transplanta-
tion, hematopoietic recovery was completely donor de-
rived. RIC regimens were defined as those in which
hematopoietic recovery was expected to occur within
28 days without transplantation and, after transplanta-
tion, chimerism could be documented in most patients.
Patients were included on the study if they had
evidence of engraftment defined as an absolute neutro-phil count (ANC).500, and received GVHD prophy-
laxis with a calcineurin inhibitor (i.e., tacrolimus or
cyclosporine) plus methotrexate (MTX). Other agents
that were allowed in the prophylaxis of aGVHD in-
cluded ATG, pentostatin, and steroids. Patients could
Biol Blood Marrow Transplant 15:1555-1562, 2009 1557Infliximab for Acute GVHDnot have received more than 48 hours of MP at a dose
of 2 mg/kg for the treatment of aGVHD or have re-
ceived any additional agents for the treatment of
aGVHD at the time of enrollment. Patients were ex-
cluded if they were receiving hemodialysis, had a con-
comitant diagnosis of congestive heart failure (even if
medically controlled), history of a demyelinating dis-
order, infection with HIV, hepatitis B, or hepatitis
C, and any uncontrolled infections. Patients with a his-
tory of tuberculosis (TB) (even latent/treated infec-
tions), a recent close contact with a person with
active TB, or chest radiograph suggestive of prior
TB were excluded from participation on the study.METHODS
Study Design
The study was a single-center, open-labeled phase
III trial with patients randomized between conven-
tional treatment with MP or MP plus infliximab.
Patients enrolled on the study were stratified based
ondonor status (matched-related versusmatched unre-
lated/mismatched-related donor) and GVHD site
(GI versus no GI GVHD involvement). All patients
signed written, informed consent prior to receiving
therapy on study. The protocol, amendments, and
informed consents documents were approved by the
institutional review board of the University of Texas,
M.D. Anderson Cancer Center.
Diagnosis and Staging of aGVHD
The diagnosis of aGVHD was made on clinical
grounds with biopsy of involved organ(s) encouraged
but not required. Patients whose biopsy specimens
confirmed a non-GVHD diagnosis were removed
from the study. When biopsy specimens failed to con-
firm the diagnosis but there was strong clinical suspi-
cion for aGVHD and other differential diagnoses
were ruled out, patients were allowed to stay in the
study. All 57 evaluable patients had their GVHD diag-
nosis confirmed by biopsy. Patients were assigned an
aGVHDgrade (I-IV) based on skin, liver, andGI stage
(I-IV) [19].
Treatment of aGVHD
Patients randomized to the control arm received
MP at a dose of 2 mg/kg/day, followed by a taper
schedule that mandated patients receive a minimum
of 1 mg/kg/day throughout the first 2 weeks of treat-
ment followed by further tapering according to depart-
mental guidelines at the discretion of the treating
physician. Methylprednisolone was initiated in both
arms at 2 mg/kg daily, and was kept at no less than
1 mg/kg daily for the first 2 weeks of therapy. Beyond
the first 2 weeks, MP was tapered by 10% to 20%weekly. Patients in the study arm received infliximab
at a dose of 10 mg/kg intravenously over 2 hours
weekly for 4 weeks in addition to MP following the
same regimen as the control group.
Follow-up and Assessment of Response
A physical exam, complete blood count (CBC), and
chemistries were required once weekly throughout the
first 30 days after enrollment on the study followed by
every 2 weeks between days 30 to 60. A formal GVHD
assessment was required twice weekly for the first 30
days followed by once weekly between days 30 to 60 af-
ter enrollment on the study. Patients were assigned an
aGVHDgrade (I-IV) based on skin, liver, and GI stage
(I-IV).
Complete response (CR) to therapy required reso-
lution of all manifestations of aGVHD. Partial
response (PR) was a decrease in organ stage by 1 with-
out worsening in any other organ. Progressive disease
(PD) was worsening by 1 in organ stage after at least
48 hours of therapy for GI and liver GVHD or
72 hours for skin GVHD. No response (NR) was ab-
sence of response after a minimum of 7 days of therapy
for skin GVHD or 3 days for GI or liver GVHD.
Amixed response (MR) was an improvement of 1 stage
in 1 affected organ with deterioration in another af-
fected organ. The response rates were determined as
the maximal response to treatment by 1 week, 2 weeks,
and 1month following initiation of treatment. Patients
who could not have formal response determined for
any reason were classified as treatment failures. All
participants initiated therapy as inpatients, and were
discharged after showing clinical improvement.
Safety Evaluation
Study drug toxicities were assessed continually
with a directed physical exam and laboratory monitor-
ing twice weekly for the first 30 days after initiation of
therapy, followed biweekly between days 30 to 60, and
then at 6 months. Adverse events (AEs) were evaluated
according to National Cancer Center (NCI) CTC
version 2.0.
Statistical Analysis
The primary objective of the trial was to determine
the response rate and toxicity of infliximab when com-
bined with MP versus steroids alone in untreated pa-
tients with aGVHD of the skin, GI, or liver. In
addition, overall survival (OS) was compared between
the 2 treatment arms at 180 days, 1 year, and 2 years
following transplant were evaluated.
Sample size determination was based on the expec-
tation that 45% of patients with newly diagnosed
aGVHD would respond to standard therapy with
MP alone based on historic data. The study was de-
signed to provide 88% power to detect an increase in
Table 2. Response to Therapy
MP Inflix + MP
N (%) N (%) P-Value
Resp at 7 days CR 13 (46) CR 8 (28) .1
PR/MR 9 (32) PR/MR 7 (24) .03
NR/PD 6 (22) NR/PD 14 (48)
Resp at 2 weeks CR 13 (46) CR 13 (45) CR5.9
PR/MR 8 (29) PR/MR 6 (21) CR/ PR/MR5.3
NR/PD 7 (25) NR/PD 10 (34)
Resp at 1 month CR 15 (54) CR 16 (55) CR5.9
PR/MR 1 (04) PR/MR 2 (07) CR/ PR/MR5.7
NR/PD 12 (43) NR/PD 11 (38)
Resp by organ at 1 month:
Skin CR/PR 13/18 (72) CR/PR 12/17 (71) Skin5.9
GI CR/PR 9/14 (64) CR/PR 10/15 (67) GI5.9
Liver CR/PR 1/3 CR/PR 0/1
Resp by severity at 1 month:
Grade II CR/PR 12/19 (63) CR/PR 12/19 (63) Grade II51.0
Grade III/IV CR/PR 4/9 (43) CR/PR 6/10 (60) Grade III/IV5.5
Required salvage treatment 14 / 28 (50) 12 / 29 (41) .5
Resp to salvage treatment CR 7 (50) CR 2 (17)
PR 1 (7) PR/MR 3 (25)
NR/PD 6 (43) NR/PD 7 (58)
CR indicates complete response; inflix, infliximab; MP, methylprednisolone; MR, mixed response; NR, no response; PD, progressive disease; PR, partial
response; Resp, response; GI, gastrointestinal.
1558 Biol Blood Marrow Transplant 15:1555-1562, 2009D. R. Couriel et al.response rate to 75% associated with the addition of
infliximab (Type I error50.05, 2 sided). The sample
size required to accept the alternative hypothesis was
70 patients. All patients who received a minimum of
1 dose of therapy were included in final analysis
whether or not they completed the planned therapy
unless they were removed from the study on account
of their biopsy suggesting a non-GVHD diagnosis
along with low clinical suspicion for aGVHD. Patients
and response characteristics were compared using
the chi-square and Fisher’s exact tests for categoric
variables and the Mann-Whitney test for continuous
variables. Actuarial OS was estimated by the Kaplan-
Meier method. The cumulative incidence method
was used to estimate the incidence of chronic
GVHD (cGVHD), disease progression, nonrelapse
mortality (NRM), and GVHD mortality accounting
for competing risks. Outcomes were compared be-
tween the 2 arms using Cox’s proportional hazards
model.RESULTS
Patient Characteristics
A total of 63 patients were enrolled in this study be-
tween August 2000 and July 2003. Six of them were re-
moved from the study after biopsies failed to identify
GVHD in the setting of low clinical suspicion. The re-
mainder 57 have their diagnosis of GVHD confirmed
by biopsy. The average age was 47 years (range: 20-
70 years). Forty of the 63 patients were male.
Twenty-eight evaluable patients were randomized to
treatment with MP and 29 patients received in-fliximab1 MP. All patients were transplanted for he-
matologic malignancies, with a comparable risk of
relapse for both groups. Patient characteristics did
not statistically differ for patients on each study arm
as represented in Table 1.Response
Response was assessed at 1 week, 2 weeks, and
1month following initiation of treatment for aGVHD.
The response at different time points is summarized
on Table 2. At 1 week the response in the infliximab
group was lower than that in patients receiving MP
alone (52% and 78%, respectively, P5.03). By
1 month, 62% of patients in the infliximab group
had maintained a response versus 58% in the MP
arm P5.7. The CR rates for aGVHD were not differ-
ent between the 2 groups at any time point. There was
no difference in response between the 2 arms based on
GVHD severity or organ involvement (Table 2). The
need and response to salvage therapy for aGVHDwere
similar in the 2 treatment arms. In the MP alone arm,
13 patients (46%) required salvage therapy, all of them
with GI GVHD. The overall response rate was 54%,
and the most common salvage treatments were inflixi-
mab (n57) and ATG (n55). Three of these 7 patients
responded to infliximab when administered as salvage
therapy, 2 of themwith a CR. In the group randomized
to infliximab1 MP a total of 10 patients (34%) re-
quired salvage therapy and 30% responded (P5.2).
The organ involvement in the 10 patients requiring
salvage therapy included isolated GI GVHD (n54),
skin GVHD (n54), liver GVHD (n51), and GI plus
liver GVHD (n51). ATG and daclizumab were
Table 3. Infectious Complications
MP (%) Inflix+ MP (%) P-Value
24 (86) 23 (79) .4
Infection type
Bacterial 20 (83) 18 (78) .2
Viral (all) 13 (54) 13 (57) .6
CMV 8 (33) 7 (30) .5
Fungal (all) 8 (33) 8 (35) .6
Aspergillus 2 (08) 2 (08) .7
Candida 3 (12) 4 (17) .5
Mycobacterium 2 (08) 1 (04) .5
CMV indicates cytomegalovirus; Inflix, infliximab; MP, methylpredniso-
lone.
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respectively).
Therapy-Related Toxicity and Infections
Therapy-related toxicities and infections were fol-
lowed for 6 months after initiation of treatment for
GVHD. There were no infusion-related reactions or
any other toxicity attributable to the administration
of infliximab. The addition of infliximab to MP as ini-
tial therapy for aGVHD did not increase the risk for
infection compared to MP alone (79% versus 86%
MP versus MP 1 infliximab, respectively, P5.4).
The frequency of bacterial, viral, or fungal infections
were also similar in both arms as shown in Table 3. Se-
rious infections, defined as those associated directly or
indirectly with death, or any invasive fungal or myco-
bacterial infections, occurred in 46% (n513) and
51% (n515) of patients (P5.7) in the MP and the
MP 1 infliximab groups, respectively.
Survival and Long-Term Complications
With a median follow-up among survivors of 59
months for the MP group and 68 months in the
infliximab1MP arm, OS was 28% and 17%, respec-
tively, P5.4 (Figure 1 and Table 4). Cumulative inci-Figure 1. CI of survival for patients with aGVHD treated with MP or
infliximab plus MP.dences (CIs) of GVHD-related mortality and NRM
were not significantly different between the 2 groups
(GVHD-related mortality: MP alone, 32% versus
infliximab1 MP, 38%, P5.6 and NRM: MP-alone,
36% versus infliximab1 MP, 52%, P5.3) (Figure 2
and Table 4). The CI at 2 years for cGVHD was sim-
ilar, with a CI of 48% in theMP arm versus 43% in the
infliximab1 MP arm, P5.9. Finally, the addition of
infliximab as initial therapy did not increase the CI
for tumor progression. Patients in the MP alone arm
had a CI for tumor progression or recurrence of
28% compared with 25% in the infliximab1 MP
arm, P5.9. In both arms, either aGVHD or cGVHD
was the most common cause of death, followed
by death because of recurrence/progression of malig-
nancy (Table 5).
Study Termination
A futility analysis with the Cochran-Mantel-
Haenszel [20] test was conducted after the accrual of
the 63rd patient (data not shown). This showed that
no significant difference would be detected between
groups after completion of accrual, even with the best
possible response to infliximab in the remainder of
patients. Thus, the study was closed prior to reaching
target accrual.DISCUSSION
aGVHD is still the main complication following
transplantation, and corticosteroids continue to be
the initial standard approach when patients cannot
be accrued into a clinical study. Infliximab, a monoclo-
nal antibody (mAb) to the soluble and transmembrane
forms of human TNF-a, has shown activity in the
treatment of steroid refractory aGVHD, particularly
in cases of GI involvement [18]. We designed a sin-
gle-center, open-labeled, randomized study of inflixi-
mab for the initial treatment of aGVHD, with the
hypothesis of a potentially higher efficacy earlier in
the treatment of GVHD.
In this trial, the addition of infliximab to cortico-
steroids in the initial treatment of aGVHD did not
provide any benefit, and response rates were similar
in both arms. Infection rate and progression of malig-
nancy were also comparable between groups. Simi-
larly, survival was not influenced by the addition of
infliximab, with only about a third of the patients
surviving in each arm.
Previous randomized studies with a similar design
included other agents in addition to corticosteroids
for the initial treatment of aGVHD. These studies
failed to showany benefit from the addition of the study
drug, and in some instances outcomes were worse.
Cragg et al. [9] randomized newly diagnosed patients
with aGVHD to receive equine ATG in addition to
Table 4. Patient Outcomes
MP Inflix + MP
p-Value
(HR, 95% CI)
Median Follow-up among
survivors (range)
59 (16-80) 68 (48-74)
100-day survival (95% CI) 82% (62-92) 76% (56-88) .6
Overall survival (95% CI) 28% (13-45) 17% (6-33) .4
Nonrelapse mortality at 2
years
36% (22-59) 52% (36-73) .3 (0.6, 0.3-1.4)
Cumulative incidence of
chronic GVHD at (95%
CI)
48% (32-71) 43% (28-66) .9 (1.1, 0.5-2.3)
Cumulative incidence of
progression at 2 years
(95% CI)
28% (15-52) 25% (13-47) .9 (1.0, 0.3-2.9)
Cumulative incidence of
death from acute GVHD
at 2 years (95% CI)
11% (4-31) 24% (13-46) .2 (0.4, 0.1-1.7)
Cumulative incidence of
death from acute or
chronic GVHD at 2 years
(95% CI)
32% (19-56) 38% (24-60) .6 (1.3, 0.4-4.8)
CI indicates confidence interval; GVHD, graft-versus-host disease; HR,
hazard ratio; Inflix, infliximab; MP, methylprednisolone.
Table 5. Causes of Death
MP N (%) Inflix + MP N (%)
P-Value
(HR, 95% CI)
Acute GVHD 3 (15) 7 (29) .2
Chronic GVHD 6 (30) 4 (17)
Infection 1 (05) 1 (04)
Relapse 9 (45) 9 (38)
Organ failure 0 (0) 1 (04)
Other/unknown 1 (05) 2 (08)
GVHD indicates graft-versus-host disease; HR, hazard ratio; CI, confi-
dence interval.
1560 Biol Blood Marrow Transplant 15:1555-1562, 2009D. R. Couriel et al.prednisone versus prednisone alone. This study found
that not only was the response rate for aGVHDnot im-
provedby theadditionofATG,butpatientshadaworse
outcome as a result of a higher frequency of infections.
More recently, Lee et al. [10] performed a randomized
study combining upfront therapy with daclizumab,
a humanizedmonoclonal antibody against the interleu-
kin 2 receptor expressed on activated T lymphocytes.
As in the ATG study, the daclizumab arm failed to im-
prove response rates in patients with aGVHD and had
a lower OS because of higher relapse and GVHD-
relatedmortality.Unlike these previous studies, the ad-
dition of infliximab in our study did not appear to either
increase the risk for infection or relapse, and survival
was not inferior in the combination arm.
One hypothesis for the failure of infliximab to
improve results in this study could be that therapy
directed at 1 specific cytokine, TNF-a, does not suffi-
ciently impact response rates, and overlaps with the0 20 40 60 80
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Figure 2. CI of NRM for patients with aGVHD treated with MP or
infliximab plus MP.broad anticytokine activity of corticosteroids. If this is
true, similar results would be expected for etanercept,
a similar anti-TNF-a antibody that has also been
studied as a treatment for aGVHD.However, an initial
report with etanercept demonstrated that this drug
might be effective when combined with corticosteroids
for patients with newly diagnosed aGVHD. In this
single-center, phase II study, the combination of eta-
nercept and corticosteroids resulted in a day 28 cumu-
lative complete response rate of 69% in65patientswith
newly diagnosed aGVHD. When these results were
then compared to the institution’s historic experience
with steroids alone, a benefit was seen for patients en-
rolled onto the trial with combination therapy. More
recently, the Blood and Marrow Clinical Trials Net-
work (BMT CTN) conducted a multicenter, random-
ized, phase II trial comparing the combination of
steroids with either etanercept, mycophenolate mofe-
til, denileukin diftitox, or pentostatin. The primary
purpose of this trial was to find the most promising
combination regimen to study in a definitive phase III
trial [21]. In this trial, patients randomized to the
MMF plus steroids arm had the highest CR rate with
60% of patients in complete response on day 28 and
73% on day 56. Despite similar design as the single
institution, phase II trial with etanercept, dissimilar
results were achieved for patients randomized to the
etanercept arm with only 26% and 44% of the 46 pa-
tients achieving a complete response by day 28 and
56, respectively. The poor results for patients enrolled
on the etanercept arm in this multicenter trial along
with the results from our randomized trial with inflixi-
mab would suggest that anti-TNF-a therapy offers lit-
tle advantage as initial therapy for patients with newly
diagnosed aGVHD.The difference between infliximab
and etanercept lies in the ability of infliximab to bind to
both soluble and transmembrane bound TNF-a,
whereas etanercept binds only to the transmembrane
form. Although such a difference would seem modest,
only a randomized phase III study with etanercept
can conclude with certainty that the lack of benefit is
not specific to infliximab alone.
The identification of patients at risk for failing ini-
tial therapy with MP alone and intensifying their ther-
apy with additional immunomodulatory drugs remains
Biol Blood Marrow Transplant 15:1555-1562, 2009 1561Infliximab for Acute GVHDa strategy for future studies. Unfortunately, in this
study, we were not able to identify any risk factors or
subset of patients that would suggest benefit from
the combination of MP and infliximab. Neither pa-
tients with severe aGVHD (grade III/IV) nor did those
patients with GI tract involvement appear to benefit
from the addition of infliximab. Correlative studies
measuring serum TNF-a levels might help to better
define those patients who may benefit from TNF-a
directed therapy. Thus, treatment could be directed
toward patients whose aGVHD is associated with
disproportionately high levels of TNF-a at diagnosis.
In support of this hypothesis, Uberti et al. [22]
demonstrated in their phase 2 study of etanercept
that a reduction in TNF-a correlated with response
to therapy. Whether this was simply a marker for re-
sponse or a direct consequence of anti-TNF-a therapy
remains untested.
The fact that now 3 randomized studies incorpo-
rating drugs that appeared effective in the steroid-
refractory setting have proved ineffective when
incorporated earlier in treatment questions such an
approach. One possibility is that broadening immuno-
suppression in the prophylaxis setting or earlier in the
course of aGVHD can impair T-regulatory cell recon-
stitution and immune tolerance as shown in preclinical
models [23]. At this time, there is no justification for
adding anti-TNF-a therapy or other forms of immu-
nomodulation to the initial therapy for aGVHD with
corticosteroids alone other than in the context of a clin-
ical trial. However, the use of immunomodulators with
a different mechanism of action and the availability of
broader antimicrobial prophylaxis could result in bet-
ter outcomes. Based on the encouraging phase II re-
sults with MMF in the BMT CTN trial, a phase III
trial with MMF is due to open in mid-2009. It remains
to be seenwhetherMMFcan succeedwhere now 3 pre-
vious tested drugs have failed.ACKNOWLEDGMENTS
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